CDSCO Implements Online System for Veterinary Drug Applications on SUGAM Portal

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-09-22 12:30 GMT | Update On 2024-09-22 12:30 GMT

New Delhi: In a significant move to streamline the regulatory submission procedure, the Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), Veterinary Division, has announced that all applications for new veterinary drug and vaccine permissions will now be processed exclusively through the online SUGAM Portal.

The notice states,

"In order to streamline the regulatory submission procedure, the submission of application for issuance of New Drug permission of Vaccines/ Drugs for Bulk (API) in Form-45A/46A and finished formulation in Form-45/46 and Field Trial Permission is now functiohial on online system ofSUGAM Portal (www.cdscoonline.gov.in)."

SUGAM is an online e-governance portal introduced by the government of India to build an in-depth regulatory framework for the registration processes of the CDSCO. This site, which has already been used by pharmaceutical companies for human drugs, will now be the primary platform for handling veterinary-related drug and vaccine permissions.

According to the circular, applicants seeking permission for new bulk (API) drugs, vaccines, finished formulations in Forms 45A/46A and 45/46, and field trial permissions must submit their applications via the online system. The previous method of submitting applications in Form-44 via hard copy or through the e-office system will no longer be accepted after August 16, 2024.

In continuation with the above, the notice states, "The applicants seeking such certificate/approval/permission shall apply through online portal as per the checklist in the developed modules. The facility of offline submission of applications in Form-44 in hard copy/through e-office may not be available for processing from 16th August 2024."

Also Read:CDSCO Panel Approves Sanofi's Protocol Amendment proposal for Fitusiran study

To view the official notice, click the link below:

https://medicaldialogues.in/pdf_upload/veterdate12sep-1-253762.pdf

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

CDSCO Implements Online System for Veterinary Drug Applications on SUGAM Portal

Similar News

Eli Lilly gets USFDA Breakthrough Therapy designation for olomorasib with Keytruda for lung cancer

NPPA fixes Special Ceiling Price for Gufic's Meropenem Dual Chamber Bags

Sun Pharma Fails to Secure CDSCO Nod for BE, Phase III Waiver on Sitagliptin, Glimepiride, Metformin FDC

USFDA approves expanded indication for Takeda Vonvendi for adults, children with Von Willebrand Disease

Roche receives EU CE mark for Contivue for neovascular age-related macular degeneration

Drug Safety Alert: IPC Flags Adverse Reactions linked to Tranexamic acid and Metoclopramide

Virchow Biotech gets CDSCO panel nod to study Semaglutide for chronic weight management

SC Questions Effectiveness of UCPMP, Seeks Govt Clarification on Pharma Freebies